Vir Biotechnology, Inc. (NasdaqGS: VIR)
Health Care · Biotechnology · US
$11.30
-3.42% today · +93.7% 1Y
Vir Biotechnology, Inc. (NasdaqGS: VIR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.98B and employs 367 people.
Over the last twelve months the share price has gained 93.7%, trading between 4.82 and 12.00.
Tweenvest scores Vir Biotechnology, Inc. across four factors: quality 37/100, value 68/100, growth 0/100. Its strongest factor is value.
VIR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.98B
- Revenue (TTM)
- $303.23M
- P/E
- —
- EPS
- -1.70
- Dividend yield
- —
- Beta (5Y)
- 1.59
- 52-week high
- $12.00
- 52-week low
- $4.82
- Avg volume (3M)
- —
- Shares outstanding
- 169.22M
- Employees
- 367
- Next earnings
- —
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
- ISIN
- US92764N1028
- Founded
- 2016
- Listed since
- Oct 11, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Palvella Therapeutics, Inc.NasdaqGM: PVLA | $2.00B | $132.75 | -4.34% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.00B | ₩48,000.00 | -6.61% |
| ADARx Pharmaceuticals, Inc.NasdaqGS: ADRX | $1.99B | $17.78 | 0.00% |
| OliX Pharmaceuticals, IncKOSDAQ: A226950 | $1.99B | ₩117,300.00 | +0.43% |
| Jinyu Bio-technology Co., Ltd.SHSE: 600201 | $1.93B | CN¥11.84 | +1.98% |
| Pell Bio-Med Technology Co., Ltd.TWSE: 6949 | $1.92B | NT$46.85 | +5.28% |
| Lakefront Biotherapeutics NVENXTAM: LKFT | $1.92B | €26.32 | +1.70% |
| Agios Pharmaceuticals, Inc.NasdaqGS: AGIO | $1.90B | $30.98 | -2.61% |
Figures last refreshed Oct 11, 2026.